Insurer Strategies to Control Costs Associated with Weight Loss Drugs
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a an analysis of 2024 federal plan data.
Search
Filter
Clear All-
-
Medicare Advantage in 2025: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior Authorization
Issue BriefThis brief provides information about Medicare Advantage plans in 2025, including premiums, out-of-pocket limits, supplemental benefits, and prior authorization, as well as trends over time.
-
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Policy WatchThis policy watch examines the implications of new proposed regulations that would allow Medicare and require Medicaid to cover drugs used to treat obesity, including a relatively new class of highly effective but costly drugs known as GLP-1s.
-
3 Charts: Drug Prices in the United States
News ReleaseThis post was updated to clarify that less than 10% of the nation's total health spending is spent on retail prescription drugs and does not include spending on drugs administrated by physicians or in hospitals.Prescription drug costs are a top concern for the American public.
-
What the Outcome of the Election Could Mean for Medicaid
Issue BriefThis brief examines the two presidential candidates’ records and other recent policy proposals that could inform starkly different directions for the program across key areas, including Affordable Care Act (ACA) Medicaid expansion, financing, eligibility, benefits, and cost-sharing, prescription drugs, long-term services and supports, and managed care.
-
Voters Chose Republicans This Year in Spite of Differences on Health Care
Quick TakeDespite [Republicans’] victories, there are signs in the polling that voters are not necessarily aligned with some of the policies Republicans may pursue when it comes to health care.
-
Americans’ Challenges with Health Care Costs
Issue BriefThis data note reviews our recent polling data that finds that Americans struggle to afford many aspects of health care, including disproportionate shares of uninsured adults, Black and Hispanic adults and those with lower incomes.
-
A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration
Issue BriefThis brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that were voted on but not enacted in the previous Congress that may return to the forefront of health policy discussions in the coming years.
-
Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans
News ReleaseAffordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data.
-
Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2024
Issue BriefThis brief analyzes 2024 Medicare Part D enrollment, premiums, and cost sharing. The analysis highlights the continued growth in Medicare Advantage enrollment in the Part D marketplace and substantially higher average monthly premiums for stand-alone Part D drug plan coverage. Changes to the Part D benefit included in the Inflation Reduction Act are helping to lower out-of-pocket costs for patients but could also contribute to higher-priced Part D coverage.